176 related articles for article (PubMed ID: 12658558)
1. Ocular penetration of acyclovir and its peptide prodrugs valacyclovir and val-valacyclovir following systemic administration in rabbits: An evaluation using ocular microdialysis and LC-MS.
Dias C; Nashed Y; Atluri H; Mitra A
Curr Eye Res; 2002 Oct; 25(4):243-52. PubMed ID: 12658558
[TBL] [Abstract][Full Text] [Related]
2. Cellular uptake mechanism of amino acid ester prodrugs in Caco-2/hPEPT1 cells overexpressing a human peptide transporter.
Han HK; Oh DM; Amidon GL
Pharm Res; 1998 Sep; 15(9):1382-6. PubMed ID: 9755889
[TBL] [Abstract][Full Text] [Related]
3. In vivo ocular pharmacokinetics of acyclovir dipeptide ester prodrugs by microdialysis in rabbits.
Anand BS; Katragadda S; Gunda S; Mitra AK
Mol Pharm; 2006; 3(4):431-40. PubMed ID: 16889437
[TBL] [Abstract][Full Text] [Related]
4. Novel dipeptide prodrugs of acyclovir for ocular herpes infections: Bioreversion, antiviral activity and transport across rabbit cornea.
Anand B; Nashed Y; Mitra A
Curr Eye Res; 2003; 26(3-4):151-63. PubMed ID: 12815543
[TBL] [Abstract][Full Text] [Related]
5. Vitreous penetration of orally administered valacyclovir.
Huynh TH; Johnson MW; Comer GM; Fish DN
Am J Ophthalmol; 2008 Apr; 145(4):682-6. PubMed ID: 18226802
[TBL] [Abstract][Full Text] [Related]
6. Ocular pharmacokinetics of acyclovir amino acid ester prodrugs in the anterior chamber: evaluation of their utility in treating ocular HSV infections.
Katragadda S; Gunda S; Hariharan S; Mitra AK
Int J Pharm; 2008 Jul; 359(1-2):15-24. PubMed ID: 18472234
[TBL] [Abstract][Full Text] [Related]
7. In vivo antiviral efficacy of a dipeptide acyclovir prodrug, val-val-acyclovir, against HSV-1 epithelial and stromal keratitis in the rabbit eye model.
Anand BS; Hill JM; Dey S; Maruyama K; Bhattacharjee PS; Myles ME; Nashed YE; Mitra AK
Invest Ophthalmol Vis Sci; 2003 Jun; 44(6):2529-34. PubMed ID: 12766053
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics of novel dipeptide ester prodrugs of acyclovir after oral administration: intestinal absorption and liver metabolism.
Anand BS; Katragadda S; Mitra AK
J Pharmacol Exp Ther; 2004 Nov; 311(2):659-67. PubMed ID: 15226381
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics of acyclovir in the cat.
Owens JG; Nasisse MP; Tadepalli SM; Dorman DC
J Vet Pharmacol Ther; 1996 Dec; 19(6):488-90. PubMed ID: 8971679
[No Abstract] [Full Text] [Related]
10. Mechanism of corneal permeation of L-valyl ester of acyclovir: targeting the oligopeptide transporter on the rabbit cornea.
Anand BS; Mitra AK
Pharm Res; 2002 Aug; 19(8):1194-202. PubMed ID: 12240946
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics of acyclovir and its metabolites in cerebrospinal fluid and systemic circulation after administration of high-dose valacyclovir in subjects with normal and impaired renal function.
Smith JP; Weller S; Johnson B; Nicotera J; Luther JM; Haas DW
Antimicrob Agents Chemother; 2010 Mar; 54(3):1146-51. PubMed ID: 20038622
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics of acyclovir after intravenous infusion of acyclovir and after oral administration of acyclovir and its prodrug valacyclovir in healthy adult horses.
Garré B; Shebany K; Gryspeerdt A; Baert K; van der Meulen K; Nauwynck H; Deprez P; De Backer P; Croubels S
Antimicrob Agents Chemother; 2007 Dec; 51(12):4308-14. PubMed ID: 17846132
[TBL] [Abstract][Full Text] [Related]
13. Acyclovir levels in serum and cerebrospinal fluid after oral administration of valacyclovir.
Lycke J; Malmeström C; Ståhle L
Antimicrob Agents Chemother; 2003 Aug; 47(8):2438-41. PubMed ID: 12878501
[TBL] [Abstract][Full Text] [Related]
14. Intra- and interindividual variabilities of valacyclovir oral bioavailability and effect of coadministration of an hPEPT1 inhibitor.
Phan DD; Chin-Hong P; Lin ET; Anderle P; Sadee W; Guglielmo BJ
Antimicrob Agents Chemother; 2003 Jul; 47(7):2351-3. PubMed ID: 12821497
[TBL] [Abstract][Full Text] [Related]
15. A sensitive liquid chromatography-tandem mass spectrometry method for the quantification of valacyclovir and its metabolite acyclovir in mouse and human plasma.
Shi J; Hu Y; Smith DE; Zhu HJ
J Chromatogr B Analyt Technol Biomed Life Sci; 2018 Aug; 1092():447-452. PubMed ID: 29945109
[TBL] [Abstract][Full Text] [Related]
16. Carrier-mediated intestinal absorption of valacyclovir, the L-valyl ester prodrug of acyclovir: 1. Interactions with peptides, organic anions and organic cations in rats.
Sinko PJ; Balimane PV
Biopharm Drug Dispos; 1998 May; 19(4):209-17. PubMed ID: 9604120
[TBL] [Abstract][Full Text] [Related]
17. Vitreal pharmacokinetics of dipeptide monoester prodrugs of ganciclovir.
Majumdar S; Kansara V; Mitra AK
J Ocul Pharmacol Ther; 2006 Aug; 22(4):231-41. PubMed ID: 16910863
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics of valacyclovir in the adult horse.
Maxwell LK; Bentz BG; Bourne DW; Erkert RS
J Vet Pharmacol Ther; 2008 Aug; 31(4):312-20. PubMed ID: 18638291
[TBL] [Abstract][Full Text] [Related]
19. Valacyclovir for herpes simplex encephalitis.
Pouplin T; Pouplin JN; Van Toi P; Lindegardh N; Rogier van Doorn H; Hien TT; Farrar J; Török ME; Chau TT
Antimicrob Agents Chemother; 2011 Jul; 55(7):3624-6. PubMed ID: 21576427
[TBL] [Abstract][Full Text] [Related]
20. Lack of a pharmacokinetic interaction between steady-state tipranavir/ritonavir and single-dose valacyclovir in healthy volunteers.
Sabo JP; Cong XJ; Kraft MF; Wallace L; Castles MA; Mauss S; MacGregor TR
Eur J Clin Pharmacol; 2011 Mar; 67(3):277-81. PubMed ID: 20963404
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]